The short version of nitric oxide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
=== Sales === US sales of the drug were of $2.2 billion in 2006. Sales in 2Q 2007 down 22% compared to 2006. 4Q 2007 sales down to $252 million. Though sales have gone down since 2007 due to safety concerns, Avandia sales for 2009 totalled $1.2 billion worldwide.
=== Carbamic acids === Many substituted carbamic acids (RHNCOOH or RR′NCOOH), can be readily synthesized by bubbling carbon dioxide through solutions of the corresponding amine (RNH2 or RR′NH, respectively) in an appropriate solvent, such as DMSO or supercritical carbon dioxide. These carbamic acids are generally unstable at room temperature, reverting to the parent amine and carbon dioxide.
=== Food additives === Potassium sodium tartrate (KNaC4H4O6, Rochelle salt) is a main constituent of some varieties of baking powder; it is also used in the silvering of mirrors. Potassium bromate (KBrO3) is a strong oxidizer (E924), used to improve dough strength and rise height. Potassium bisulfite (KHSO3) is used as a food preservative, for example in wine and beer-making (but not in meats). It is also used to bleach textiles and straw, and in the tanning of leathers.
SpyTag and SpyCatcher were formed from the splitting and engineering of the CnaB2 domain of the FbaB protein from Streptococcus pyogenes, which naturally forms an intramolecular isopeptide bond to assist colonization of the host cell. With the formation of the isopeptide bond, the CnaB2 domain becomes more tolerant to conformational, thermal and pH changes. Building upon this, SpyTag was obtained from CnaB2 by extracting the C-terminal beta strand containing the reactive aspartic acid at D556 and leaving the rest of the beta strands containing the reactive lysine K470 and the catalytic glutamic acid at E516 to become SpyCatcher, after further engineering to remove some hydrophobic surface residues. The resulting SpyTag/SpyCatcher can react to form the isopeptide bond with a second-order rate constant of 1.4 ± 0.4 × 103 M−1 s−1. It is postulated that the reaction mechanism proceeds by a nucleophilic attack on D556 from K470, mediated by E516. By reconstituting SpyTag:SpyCatcher, the resulting conjugated complex acquires the stability of the parent CnaB2 domain. A second generation SpyTag/SpyCatcher called SpyTag002/SpyCatcher002 was then created through phage display that enables the peptide-protein pair to react up to 12 times faster than the original pair, at a rate constant of 2.0 ± 0.2 × 104 M−1 s−1. The second generation SpyCatcher002 also has abolished self-reactivity that is present with SpyCatcher. A third generation SpyTag/SpyCatcher called SpyTag003/SpyCatcher003 has now also been created through rational design.
== Portal site mediated adsorption == Portal site mediated adsorption is a model for site-selective activated gas adsorption in metallic catalytic systems that contain a variety of different adsorption sites. In such systems, low-coordination "edge and corner" defect-like sites can exhibit significantly lower adsorption enthalpies than high-coordination (basal plane) sites. As a result, these sites can serve as "portals" for very rapid adsorption to the rest of the surface. The phenomenon relies on the common "spillover" effect (described below), where certain adsorbed species exhibit high mobility on some surfaces. The model explains seemingly inconsistent observations of gas adsorption thermodynamics and kinetics in catalytic systems where surfaces can exist in a range of coordination structures, and it has been successfully applied to bimetallic catalytic systems where synergistic activity is observed. In contrast to pure spillover, portal site adsorption refers to surface diffusion to adjacent adsorption sites, not to non-adsorptive support surfaces. The model appears to have been first proposed for carbon monoxide on silica-supported platinum by Brandt et al. (1993). A similar, but independent model was developed by King and co-workers to describe hydrogen adsorption on silica-supported alkali promoted ruthenium, silver-ruthenium, and copper-ruthenium bimetallic catalysts. The same group applied the model to CO hydrogenation (Fischer–Tropsch synthesis). Zupanc et al.
Sources: en.wikipedia.org
Through discretionary grants, federal agencies set program objectives, eligibility criteria, and funding conditions in Notices of Funding Opportunity (NOFOs), which can shape how artificial intelligence technologies are developed and deployed by funding recipients. Guidance issued by the Office of Management and Budget (OMB) to implement the Executive Order's policies applied risk-management requirements primarily to procurement and agency uses of AI, while generally excluding federal financial assistance programs. In April 2024, the Federal Trade Commission (FTC) announced Operation AI Comply, a cross-agency initiative to ensure that AI products and marketing claims comply with existing consumer-protection, fair-credit, and truth-in-advertising laws. The FTC stated that companies deploying AI systems must "keep their AI claims in check" and warned that false or misleading representations about AI capabilities would be subject to enforcement under the FTC Act. In 2024, a bipartisan House task force released a report on artificial intelligence, while representatives Jay Obernolte and Lori Trahan subsequently developed a bipartisan proposal concerning AI regulation.
By interchanging the Arg-1, Lys-3, and Asp-8 residues to see if their positions are essential for sodium channel binding or formation of the secondary structure, inactive peptides were obtained which proposes that correct positioning of these residues is critical for activity. The introduction of disulfide bonds in the kink structure to make it less flexible also led to inactive peptides as they appeared to be very sensitive to structural changes. However, a peptide where Lys-3 was replaced with a more basic Arg residue showed better activity. This was designed based on observations that some of the acidic residues in the neuronal sodium channels are important for binding and that removal of basic residue Lys-3 from α-PMTX was not tolerated, while removal of acidic residue Asp-8 was. By combining K3R (lysine-3 to arginine) and S11L (serine-11 to leucine) mutations, a higher activity could also be obtained. Lipophilic residues in other toxins that block sodium channels have been assumed to be important for binding at site 3 of neuronal sodium channels. Additionally, it was found that replacing Phe-7 of β-PMTX with more lipophilic amino non-natural amino acids such as 1-Nal and 2-Nal resulted in a boost in activity, while replacement with a polar residue led to a complete loss of activity. This suggests an essential role of the endogenous Phe-7 residue in mediating the interaction between the venom toxin and the sodium channel.
=== Detection in body fluids === Buprenorphine and norbuprenorphine may be quantified in blood or urine to monitor use or non-medical recreational use, confirm a diagnosis of poisoning, or assist in a medicolegal investigation. A significant overlap of drug concentrations exists in body fluids within the possible spectrum of physiological reactions ranging from asymptomatic to comatose. Therefore, knowing both the route of administration of the drug and the level of tolerance to opioids of the individual is critical when results are interpreted.
Taxifolin (5,7,3',4'-flavan-on-ol), also known as dihydroquercetin, belongs to the subclass flavanonols in the flavonoids, which in turn is a class of polyphenols. It is extracted from plants such as Siberian larch and milk thistle.
Following comprehensive lifestyle modifications, the average maintained weight loss is more than 3 kg (6.6 lb) or 3% of total body mass, and could be sustained for five years, and up to 20% of the individuals maintain a weight loss of at least 10% (average of 33 kg). There is some evidence that fast weight loss produce greater long-term weight loss than gradual weight loss. Moderate on-site comprehensive lifestyle changes produce a greater weight loss than usual care, of 2 to 4 kg on average in 6 to 12 months. High-intensity comprehensive programs usually yield more weight loss than moderate or low-intensity, with about 35% to 60% of overweight individuals maintaining more than 5 kg weight loss after 2 years. The NICE devised a set of essential criteria to be met by commercial weight management organizations to be approved. The Transtheoretical Model (TTM) has been used as a framework to assist the design of lifestyle modification programmes, including weight management. A systematic review found that there is insufficient evidence to draw conclusions regarding the effects of TTM-based programs targeting weight loss that included dietary or physical activity interventions, or both (and also combined with other interventions), on sustainable weight loss (one year or longer) in overweight and obese adults. However, very low quality evidence points that this approach may induce positive changes in physical activity and dietary habits, such as increased in exercise duration and frequency, improvement in fruits and vegetables consumption, and reduced dietary fat intake.
Sources: en.wikipedia.org
=== 2010s === In 2010, Grace received approval from the U.S. Bankruptcy Court for the merger with Synthetec, which is a company that had developed and manufactured amino acid and peptide products as well as proprietary custom chiral intermediates primarily for the pharmaceutical industry. In 2014, the Grace bankruptcy process terminated. However, some legal procedures continued into the next decade. In February 2016, Grace completed the corporate spin-off of GCP Applied Technologies, which was also as a public trading corporation on the NYSE. Grace shareholders receive GCP stock on 1:1 ratio. GCP Applied Technologies consisted of the concrete admixture and related products company Grace Construction Products (GCP) and Darex, a packaging technologies business unit. In July 2016, Grace acquired the global polyolefin catalysts business unit from BASF.
=== Effects of the Napoleonic Wars === In 1808, Napoleon Bonaparte, as part of his Continental Blockade strategy against the British Empire, forced the Spanish royal family to abdicate the throne, imposed the Bayonne Statute, and installed his brother, Joseph Bonaparte, as King of Spain. In the 18th century, the Habsburg dynasty was replaced by the Bourbons, and the Spanish Empire declined from a global power to a second-rate power following the War of the Spanish Succession, but continued to be an important colonial power due to its possessions in the Americas. Similarly, the replacement of the Bourbons with the Bonaparte dynasty aimed to preserve the empire's integrity. Napoleon showed an interest in retaining the American viceroyalties even before placing Joseph I on the Spanish throne in 1808, attracted by their resources and commercial potential. His policy towards Spanish America initially took shape through two simultaneous initiatives: the dispatch of commissioners to the viceroyalties and the summoning of American representatives to the Assembly of Bayonne. However, Napoleonic Spain (1808–1813) was ultimately defeated in the Peninsular War. The rejection of this new dynasty created a power vacuum and led to the emergence of liberalism and a desire for liberties throughout the Spanish Empire.
After independence in 1947, Jinnah, the president of the Muslim League, became Pakistan's first governor-general and the first President-Speaker of the Parliament, but he died of tuberculosis on 11 September 1948. Meanwhile, Pakistan's founding fathers agreed to appoint Liaquat Ali Khan, the secretary-general of the party, the nation's first prime minister. From 1947 to 1956, Pakistan was a monarchy within the Commonwealth of Nations, and had two monarchs before it became a republic. The creation of Pakistan was never fully accepted by many British leaders, including Lord Mountbatten. Mountbatten expressed his lack of support and faith in the Muslim League's idea of Pakistan. Jinnah refused Mountbatten's offer to serve as Governor-General of Pakistan. When Mountbatten was asked by Collins and Lapierre if he would have sabotaged Pakistan had he known that Jinnah was dying of tuberculosis, he replied 'most probably'.
The word pharmacology is derived from Greek word φάρμακον, pharmakon, meaning "drug" or "poison", together with another Greek word -λογία, logia with the meaning of "study of" or "knowledge of" (cf. the etymology of pharmacy). Pharmakon is related to pharmakos, the ritualistic sacrifice or exile of a human scapegoat or victim in Ancient Greek religion. The modern term pharmacon is used more broadly than the term drug because it includes endogenous substances, and biologically active substances which are not used as drugs. Typically it includes pharmacological agonists and antagonists, but also enzyme inhibitors (such as monoamine oxidase inhibitors).
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.